Literature DB >> 377958

Drug therapy reviews: antirheumatic agents.

R P Evens.   

Abstract

The pathophysiology, symptoms and drug treatment of rheumatic disease are reviewed. Antirheumatic drugs reviewed are salicylates (including aspirin, sodium salicylate, choline salicylate, choline magnesium salicylate, salsalate), phenylpropionic acid derivatives (fenoprofen, ibuprofen, naproxen), indole derivatives (sulindac, tolmetin and indomethacin), pyrazolone derivatives (phenylbutazone, oxyphenbutazone), gold compounds, penicillamine, antimalarials mefenamic acid, corticosteroids and immunosuppressives. Simple analgesic therapy (acetaminophen, aspirin, propoxyphene) is used in the early stage of the disease. As the disease progresses, aspirin remains the drug of choice for antiinflammatory activity but the phenylpropionic acid or indole derivatives may be preferred in patients unable to tolerate salicylates. If such nonsteroidal antiinflammatory agents are not effective, parenteral therapy with gold compounds or oral penicillamine usually is indicated. Indomethacin or phenylbutazone, then antimalarials, are resorted to next. Corticosteroids or immunosuppressives are reserved for patients who are unsuccessfully controlled or who have major side effects with the other drugs. Mefenamic acid occupies a very secondary place in rheumatoid arthritis treatment.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 377958

Source DB:  PubMed          Journal:  Am J Hosp Pharm        ISSN: 0002-9289


  2 in total

1.  Isopropyl 2-[2-(2,6-dichloro-anilino)phen-yl]acetate.

Authors:  Hamid Nawaz; M Khawar Rauf; Masahiro Ebihara; Amin Badshah
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2007-12-21

2.  BF3-OEt2 Catalyzed C3-Alkylation of Indole: Synthesis of Indolylsuccinimidesand Their Cytotoxicity Studies.

Authors:  Iqbal N Shaikh; Abdul Rahim; Shaikh Faazil; Syed Farooq Adil; Mohamed E Assal; Mohammad Rafe Hatshan
Journal:  Molecules       Date:  2021-04-11       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.